Hexapeptide-44
/ Synthetic hexapeptide; INCI 'Hexapeptide-44'; lamin B1 upregulating cosmetic peptideALIAS · Hexalin (trade) · Hexapeptide-44 (INCI)
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Industry-authored cosmetic ingredient. The supplier marketing literature describes lamin B1 upregulation in skin fibroblast cultures as the proposed anti-senescence mechanism. PubMed-indexed primary literature on Hexapeptide-44 specifically is sparse to absent; the molecule is documented mainly in supplier dossiers and INCI/cosmetic-trade publications.
Hexapeptide-44 is described in supplier technical literature as an upregulator of lamin B1 — a nuclear-envelope intermediate filament protein whose decline is associated with replicative senescence in dermal fibroblasts. The proposed mechanism is restoration of nuclear-envelope integrity in aged fibroblasts, with downstream effects on chromatin organisation and gene-expression patterns characteristic of younger cells. Independent peer-reviewed mechanism characterisation is limited.
Tier 4. Supplier-authored in-vitro fibroblast studies and trade-publication summaries are the primary evidence sources. PubMed-indexed independent replication and controlled human topical-efficacy trials are not readily available.
No published independent safety database. Cosmetic INCI status implies acceptance for topical use in finished products under standard cosmetic-ingredient regulatory frameworks; this is not the same as a clinical safety dataset.
Regulatory status
- FDA status:
- Not FDA-approved
The lamin B1 mechanism is biologically plausible (lamin B1 loss is a documented senescence marker) but the published evidence that topical Hexapeptide-44 modulates lamin B1 in human skin in vivo is industry-authored. Independent peer-reviewed replication of the mechanism and clinical-grade efficacy data are limited.